Network Meta-analysis of Chinese Herbal Injections Combined with the Chemotherapy for the Treatment of Pancreatic Cancer

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2017 May 25

PMID 28538415

Citations 27

Authors

Dan Zhang

Jiarui Wu

Shi Liu

Xiaomeng Zhang

Bing Zhang

Affiliations

Soon will be listed here.

Abstract

Background: This study sought to use a network meta-analysis to assess the effectiveness and safety of Chinese herbal injections (CHIs) combined with the chemotherapy for the treatment of pancreatic cancer.

Methods: Randomized controlled trials (RCTs) regarding CHIs to treat pancreatic cancer were searched in PubMed, the Cochrane library, Embase, the China National Knowledge Infrastructure Database (CNKI), the Wan-Fang Database, the Chinese Scientific Journals Full-text Database (VIP), and the Chinese Biomedical Literature Database (SinoMed) up to November 2016. The quality assessment was conducted by the Cochrane risk of bias tool and network meta-analysis was performed to compare the effectiveness and safety of different CHIs combined with the chemotherapy. Data were analyzed using STATA 12.0 and Win-BUGS 1.4 software.

Results: A total of 278 records were searched, and 22 eligible RCTs involving 1329 patients and 9 CHIs were included. The results of the network meta-analysis demonstrated that compared with the chemotherapy alone, Compound Kushen, Kangai or Kanglaite injection combined with chemotherapy yielded significantly higher probability of improving performance status. Aidi injection combined with chemotherapy was more effective in relieving leucopenia than using chemotherapy single. And these between-group differences were statistically significant. However, CHIs combined with chemotherapy could not achieve a better effect in the total clinical effect, nausea and vomiting. As for the cluster analysis for the adverse reactions (ADRs), the chemotherapy alone and Huachansu injection combined with the chemotherapy were inferior to relieve ADRs than the other CHIs plus chemotherapy for patients with pancreatic cancer.

Conclusions: The current evidence showed that using CHIs on the basis of the chemotherapy could be beneficial for patients with pancreatic cancer in improving performance status and reducing the ADRs.

Citing Articles

Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery.

Wu J, Tang G, Cheng C, Yeerken R, Chan Y, Fu Z Mol Cancer. 2024; 23(1):218.

PMID: 39354529 PMC: 11443773. DOI: 10.1186/s12943-024-02136-2.

Effect of different interventions on the treatment of high-risk human papillomavirus infection: a systematic review and network meta-analysis.

Wang D, Cui Y, Zhang W, Fan M, Qiu K, Yan L Front Med (Lausanne). 2024; 11:1274568.

PMID: 38420364 PMC: 10899477. DOI: 10.3389/fmed.2024.1274568.

Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer - An Overview.

Tarasiuk A, Mirocha G, Fichna J Curr Treat Options Oncol. 2023; 24(12):1852-1869.

PMID: 38079061 PMC: 10781793. DOI: 10.1007/s11864-023-01146-4.

Chinese herbal injections in combination with radiotherapy for advanced pancreatic cancer: A systematic review and network meta-analysis.

Chen Y, Zhao R, Xu Y, Ma Y, Hu S, Wang X Integr Med Res. 2023; 12(4):101004.

PMID: 38033651 PMC: 10681939. DOI: 10.1016/j.imr.2023.101004.

Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis.

Liu S, Zhang K, Hu X Front Pharmacol. 2022; 13:1004259.

PMID: 36523501 PMC: 9745148. DOI: 10.3389/fphar.2022.1004259.

References

Perrin M, Terry M, Kleinhaus K, Deutsch L, Yanetz R, Tiram E . Gestational diabetes as a risk factor for pancreatic cancer: a prospective cohort study. BMC Med. 2007; 5:25. PMC: 2042496. DOI: 10.1186/1741-7015-5-25. View

Salanti G, Dias S, Welton N, Ades A, Golfinopoulos V, Kyrgiou M . Evaluating novel agent effects in multiple-treatments meta-regression. Stat Med. 2010; 29(23):2369-83. DOI: 10.1002/sim.4001. View

Miller A, Hoogstraten B, STAQUET M, Winkler A . Reporting results of cancer treatment. Cancer. 1981; 47(1):207-14. DOI: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. View

Wang W, You R, Qin W, Hai L, Fang M, Huang G . Anti-tumor activities of active ingredients in Compound Kushen Injection. Acta Pharmacol Sin. 2015; 36(6):676-9. PMC: 4594177. DOI: 10.1038/aps.2015.24. View

Bhatnagar N, Lakshmi P, Jeyashree K . Multiple treatment and indirect treatment comparisons: An overview of network meta-analysis. Perspect Clin Res. 2014; 5(4):154-8. PMC: 4170532. DOI: 10.4103/2229-3485.140550. View

Cope S, Jansen J . Quantitative summaries of treatment effect estimates obtained with network meta-analysis of survival curves to inform decision-making. BMC Med Res Methodol. 2013; 13:147. PMC: 3866977. DOI: 10.1186/1471-2288-13-147. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Migliore A, Broccoli S, Massafra U, Bizzi E, Frediani B . Mixed-treatment comparison of anabolic (teriparatide and PTH 1-84) therapies in women with severe osteoporosis. Curr Med Res Opin. 2012; 28(3):467-73. DOI: 10.1185/03007995.2012.659724. View

Larsson S, Giovannucci E, Wolk A . Methionine and vitamin B6 intake and risk of pancreatic cancer: a prospective study of Swedish women and men. Gastroenterology. 2007; 132(1):113-8. DOI: 10.1053/j.gastro.2006.10.017. View

10.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View

11.

Meng Z, Garrett C, Shen Y, Liu L, Yang P, Huo Y . Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas. Br J Cancer. 2012; 107(3):411-6. PMC: 3405220. DOI: 10.1038/bjc.2012.283. View

12.

Louvet C, Labianca R, Hammel P, Lledo G, Zampino M, Andre T . Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005; 23(15):3509-16. DOI: 10.1200/JCO.2005.06.023. View

13.

Burris 3rd H, Moore M, Andersen J, Green M, Rothenberg M, Modiano M . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15(6):2403-13. DOI: 10.1200/JCO.1997.15.6.2403. View

14.

Lumley T . Network meta-analysis for indirect treatment comparisons. Stat Med. 2002; 21(16):2313-24. DOI: 10.1002/sim.1201. View

15.

Genkinger J, Spiegelman D, Anderson K, Bergkvist L, Bernstein L, van den Brandt P . Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev. 2009; 18(3):765-76. PMC: 2715951. DOI: 10.1158/1055-9965.EPI-08-0880. View

16.

Liu Y, Zhang W, Wang X, Liu S . Antitumor effect of Kanglaite® injection in human pancreatic cancer xenografts. BMC Complement Altern Med. 2014; 14:228. PMC: 4105135. DOI: 10.1186/1472-6882-14-228. View

17.

Berlin J, Catalano P, Thomas J, Kugler J, Haller D, Benson 3rd A . Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002; 20(15):3270-5. DOI: 10.1200/JCO.2002.11.149. View

18.

Zhang H, Zhou Q, Lu Y, Du J, Su S . Aidi injection alters the expression profiles of microRNAs in human breast cancer cells. J Tradit Chin Med. 2011; 31(1):10-6. DOI: 10.1016/s0254-6272(11)60003-4. View

19.

Salanti G, Higgins J, Ades A, Ioannidis J . Evaluation of networks of randomized trials. Stat Methods Med Res. 2007; 17(3):279-301. DOI: 10.1177/0962280207080643. View

20.

Jansen J, Naci H . Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med. 2013; 11:159. PMC: 3707819. DOI: 10.1186/1741-7015-11-159. View